论文部分内容阅读
回顾性分析了武汉地区部分医院近5年来溶栓或非溶栓治疗对455例急性心肌梗塞(AMI)患者病死率的影响。结果显示静脉给予尿激酶可降低AMI近期病死率。尿激酶剂量>90万U组的病死率比<90万U组低,早期溶栓比延迟溶栓的疗效好,说明合理使用尿激酶静脉溶栓,可提高AMI的存活率,改善病人的预后。
We retrospectively analyzed the impact of thrombolytic or non-thrombolytic therapy in 455 patients with acute myocardial infarction (AMI) in some hospitals in Wuhan in the past five years. The results showed that intravenous administration of urokinase can reduce the recent mortality of AMI. Urokinase dose> 90 million U group of mortality than <90 million U group, early thrombolysis delayed thrombolytic effect than good, indicating that the rational use of intravenous thrombolytic urokinase can improve the survival rate of AMI and improve the patient’s prognosis .